NCT03853733 Hypofractionated Palliative Radiotherapy in Patients With Advanced Non-operable Rectal Cancer
| NCT ID | NCT03853733 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Consorci Sanitari de Terrassa |
| Condition | Rectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2016-10-01 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2016-10-01 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Many patients with rectal cancer were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases. In this scenario only comfort measures or different palliative radiotherapy regimens are applied, from single doses to treatments lasting several weeks. The aim of this prospective study is to describe the preliminary results of our protocol of hypofractionated palliative radiotherapy in patients with non-operable rectal cancer.
Eligibility Criteria
Inclusion criteria : 1. Patients with rectal or sigmoidal cancer who were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases at the time of diagnosis 2. Patients with = or \> 18 years old 3. Patients treated with a radiotherapy dose of 39Gy in 13 fractions of 3 Gy Exclusion criteria: 1. Patients with a non rectum or sigma colo-rectal cancer. 2. Patients with \<18 years old. 3. Patients treated with concurrent chemotherapy 4. Patients candidates for surgical resection after radiotherapy
Contact & Investigator
Joan Lozano, MD
PRINCIPAL INVESTIGATOR
Consorci Sanitari de Terrassa
Frequently Asked Questions
Who can join the NCT03853733 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03853733 currently recruiting?
Yes, NCT03853733 is actively recruiting participants. Contact the research team at jlozano@cst.cat for enrollment information.
Where is the NCT03853733 trial being conducted?
This trial is being conducted at Terrassa, Spain.
Who is sponsoring the NCT03853733 clinical trial?
NCT03853733 is sponsored by Consorci Sanitari de Terrassa. The principal investigator is Joan Lozano, MD at Consorci Sanitari de Terrassa. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.